Neoadjuvant chemoimmunotherapy achieves higher pathological complete response rates than chemotherapy alone in muscle-invasive bladder cancer
Chemoimmunotherapy Shows Higher Response Rates in Bladder Cancer
This network meta-analysis of 2234 patients with muscle-invasive bladder cancer compares neoadjuvant chemoimmunotherapy (NICT), chemotherapy…
A new analysis shows that combining chemotherapy and immunotherapy may lead to higher response rates for patients with muscle-invasive bladd…
Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
Machine learning models predict how well lung cancer patients respond to immunotherapy
This systematic review and meta-analysis of 44 models found that machine learning predicts neoadjuvant immunotherapy response in resectable …
A new analysis of 44 models shows computer programs can guess which lung cancer patients will benefit from immunotherapy, though the study h…
Systemic cancer treatment linked to 5% skeletal muscle loss over 90 days
Cancer treatment linked to muscle loss in large analysis
A systematic review and meta-analysis of 78 studies (n=10,502) found that systemic cancer treatment is associated with a small but significa…
Chemotherapy and immunotherapy may cause muscle loss in cancer patients, a new analysis of 78 studies finds.
Giant mesenteric fibromatosis progresses despite targeted therapy and immunotherapy in case report
One patient with a giant tumor progressed despite targeted therapy and immunotherapy
This review of a case report describes a patient with giant abdominal mesenteric fibromatosis who progressed rapidly despite targeted therap…
A single patient with a massive abdominal tumor saw it grow quickly even after receiving advanced drugs, followed by complex surgery.
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Case report details multimodal treatment for aggressive thyroid carcinoma
First new treatment combination in six months stabilizes advanced thyroid cancer
A 61-year-old man with papillary thyroid carcinoma achieved disease stabilization after thyroidectomy, radiotherapy, and targeted therapy. T…
A 61-year-old man with advanced thyroid cancer saw his disease stop growing after a specific mix of treatments within six months of his diag…
Case report and literature review of thymoma associated with stiff person syndrome and myasthenia gravis
A Rare Muscle Stiffness Link to Thymoma Tumor Explained
This case report and literature review examines the association between thymoma and autoimmune syndromes including stiff person syndrome and…
A rare mix of muscle stiffness and weakness was traced to a thymoma tumor, with new genetic clues pointing to a shared immune cause.
Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
New Kidney Cancer Rules Change How Doctors Treat Metastasis
This guideline presents a consensus statement developed by 6 urologists and 8 clinical oncologists in Hong Kong regarding locally advanced a…
New expert rules update kidney cancer care with more drug options and clearer surgery plans.
Review of case report showing durable response after surgery in metastatic bladder SqCC
She Was Offered Hospice. Surgery Gave Her Two More Years Instead
This narrative review synthesizes a single case report of a 65-year-old woman with metastatic squamous cell carcinoma of the bladder.
A woman with a rare, drug-resistant bladder cancer that had spread to both lungs chose surgery when hospice was offered — and two years late…
Combining chemotherapy, immunotherapy, and high-dose radiation achieved remission in a patient with cervical esophageal adenocarcinoma
Rare throat cancer vanishes after bold three-pronged treatment
This case report describes a 39-year-old male with cervical esophageal adenocarcinoma treated with standard chemotherapy and immunotherapy c…
A 39-year-old man with rare throat cancer reached complete remission after doctors combined chemo, immunotherapy, and high-dose radiation.